Clinical Efficacy and Safety of Mesenchymal Stem Cells for Systemic Lupus Erythematosus
Table 1
Characteristics of the studies included in this meta-analysis.
Author, year
Study type
Basic regimen
Patient characteristics
MSC
MSC dose
Infusion
Endpoint
Adverse events
Effectiveness
Yang, 2014
RCT
GC+CTX
Refractory SLE
UC-MSC
, once
IV
SLEDAI, proteinuria, Scr, serum albumin, C3, C4
—
Yes
Zeng, 2016
RCT
GC+MMF
II-IV type of LN
UC-MSC
/kg, 3-5 times
Renal artery
SLEDAI, proteinuria, Scr, serum albumin, C3, C4, BUN
—
Yes
Tang, 2016
RCT
GC+MMF+CTX
IV type of LN
UC-MSC
, twice
IV
SLEDAI, proteinuria
T (): 1 case with upper respiratory tract infection, 1 case of right thigh abscess; C (): 1 case with upper respiratory tract infection
No
Deng, 2017
RCT
GC+CTX
IV type of LN
UC-MSC
IV
Proteinuria, Scr
T (): one with leucopenia and pneumonia together with subcutaneous abscess. Another with severe pneumonia; C (): one patient with stroke and another with ascites of unknown cause
No
Gu, 2014
Self-control
GC+CTX/MMF
Refractory SLE
BM-MSC, UC-MSC
/kg, once
IV
SLEDAI, proteinuria, Scr, BUN
Enteritis, diarrhea, transient increase of serum creatinine, herpes virus infection. But, none of them were considered to be related to MSC infusion
Yes
Zhu, 2016
Self-control
GC+CTX/MMF
Refractory SLE
UC-MSC
, twice
IV
SLEDAI, Scr, BUN, C4
Adverse event was not found
Yes
Li, 2016
Self-control
GC+CTX
III-IV type of LN or with type V
UC-MSC
/kg-/kg, 4 times
IV
SLEDAI, proteinuria, Scr, C3, C4
Two cases of fever, 2 cases of diarrhea, 1 case of vomiting, 1 case of pruritus
Yes
Qiu, 2016
Self-control
GC+CTX/MMF
Refractory SLE
UC-MSC
/kg, once
IV
SLEDAI, proteinuria, C3
Adverse event was not found
Yes
Bai, 2017
Self-control
GC+CTX/MMF
Refractory SLE
UC-MSC
/kg, 3-5 times
IV
SLEDAI, proteinuria, C3, C4
One patient with headache, nausea, and vomiting during each stem cell infusion
